KY
KYKOF.US Kyowa Kirin Co. Ltd
- Market cap
- USD 8.53B
- P/E
- 16.1x
- P/B
- 1.49x
- ROE
- 7.6%
- Dividend yield
- 2.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KYKOF.US undervalued?
Graham numberKYKOF.US trades 3.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyowa Kirin Co. Ltd fundamental analysis
No fundamental analysis for Kyowa Kirin Co. Ltd yet.
Kyowa Kirin Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyowa Kirin Co. Ltd
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for th…
Full company profileKyowa Kirin Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyowa Kirin Co. Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 343B | 353B | 347B | 306B | 318B | 352B | 398B | 442B | 496B | 497B | 515B |
| Gross Profit | 208B | 224B | 227B | 226B | 238B | 264B | 311B | 331B | 363B | 369B | 374B |
| Operating Income | 31.6B | 57.7B | 75.0B | 45.8B | 59.0B | 61.2B | 82.4B | 86.4B | 91.9B | 102B | 118B |
| EBITDA | 67.1B | 84.5B | 84.5B | 64.6B | 74.7B | 79.9B | 87.1B | 117B | 116B | 116B | 148B |
| Net Income | 18.7B | 42.9B | 54.4B | 67.1B | 47.0B | 52.3B | 53.6B | 81.2B | 59.9B | 67.1B | 69.1B |
| EPS | 34 | 78 | 101 | 124 | 87 | 97 | 100 | 151 | 113 | 128 | 132 |
| Balance Sheet | |||||||||||
| Total Assets | 697B | 708B | 742B | 784B | 801B | 922B | 940B | 1.03T | 1.07T | 1.11T | 1.09T |
| Total Liabilities | 96.4B | 92.3B | 92.4B | 106B | 103B | 185B | 177B | 190B | 217B | 215B | 181B |
| Shareholders' Equity | 601B | 616B | 650B | 678B | 698B | 737B | 763B | 836B | 851B | 894B | 913B |
| Cash & Short-term Investments | 13.1B | 15.2B | 16.6B | 21.2B | 288B | 337B | 340B | 405B | 246B | 219B | 242B |
| Total Debt | 5.36B | 2.82B | 2.53B | 18.1B | 779M | 22.5B | 21.6B | 19.3B | 138M | 26.2B | 19.5B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 65.8B | 64.9B | 56.2B | 53.7B | 39.5B | 86.5B | 48.7B | 116B | 67.9B | 100B | 115B |
| Capital Expenditure | 29.2B | 22.3B | 20.1B | 21.3B | 35.2B | 19.8B | 28.7B | 32.9B | 105B | 41.1B | 35.1B |
| Free Cash Flow | 36.5B | 42.6B | 36.0B | 32.4B | 4.27B | 66.8B | 20.0B | 82.7B | -37.4B | 59.0B | 80.2B |
| Ratios | |||||||||||
| ROE | 3.1% | 7.0% | 8.4% | 9.9% | 6.7% | 7.1% | 7.0% | 9.7% | 7.0% | 7.5% | 7.6% |
| ROA | 2.7% | 6.1% | 7.3% | 8.6% | 5.9% | 5.7% | 5.7% | 7.9% | 5.6% | 6.1% | 6.3% |
| Net Profit Margin | 5.4% | 12.1% | 15.7% | 21.9% | 14.8% | 14.9% | 13.4% | 18.4% | 12.1% | 13.5% | 13.4% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.03x | 0.00x | 0.03x | 0.03x | 0.02x | 0.00x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kyowa Kirin Co. Ltd dividends
- Dividend yield
- 2.69%
- Forward dividend
- 0.44 USD
- Payout ratio
- 46.1%
- Ex-dividend date
- Dec 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | JPY 30.9B | 59 | 46.1% |
| 2024 | JPY 30.9B | 58 | 51.6% |
| 2023 | JPY 29.0B | 54 | 35.8% |
| 2022 | JPY 25.3B | 47 | 47.1% |
| 2021 | JPY 24.2B | 45 | 46.2% |
| 2020 | JPY 23.6B | 44 | 50.2% |
| 2019 | JPY 21.7B | 40 | 32.3% |
| 2018 | JPY 16.1B | 30 | 29.7% |
| 2017 | JPY 13.7B | 25 | 31.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Kyowa Kirin Co. Ltd
- Insiders 55.72%
- Institutions 18.99%
- Public & others 25.29%
- Shares outstanding 524M
- Free float 234M
Kyowa Kirin Co. Ltd company profile
- Company name
- Kyowa Kirin Co. Ltd
- Ticker
- KYKOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,161
- Fiscal year end
- December
- Address
- Otemachi Financial City Grand Cube, Chiyoda, Japan, 100-0004
- Phone
- 81 3 5205 7200
- Website
- kyowakirin.com
About Kyowa Kirin Co. Ltd
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Kyowa Kirin Co. Ltd management
10- Dr. Abdul Hafeez Mullick Ph.D.President, CEO & Representative Director · born 1967
- Mr. Koji IgarashiChief Financial Officer
- Naohiko KuboGlobal Finance Head & Accounting Manager
- Nobuyuki ManitaHead of IR Group
- Kazuki NemotoHead of Global Legal
- Takaaki Uochi Ph.D.Head of Global Compliance & Risk Management
- Stacey MintonGlobal Corporate Communications Head
- Ms. Shoko ItagakiManaging Executive Officer, Chief People Officer & Global Human Resources Head
- Mr. Takeyoshi Yamashita Ph.D.Executive VP, Chief Scientific Officer & Director · born 1961
- Yasuo Fujii M.B.A.Chief Business Officer, VP & Managing Executive Officer · born 1964